| Serial Number | 79188650 |
| Word Mark | ANEMOCYTE |
| Filing Date | Friday, September 11, 2015 |
| Status | 706 - SECTION 71 ACCEPTED |
| Status Date | Friday, February 28, 2025 |
| Registration Number | 5215720 |
| Registration Date | Tuesday, June 6, 2017 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 21, 2017 |
| Goods and Services | [ Surgical apparatus and instruments for medical, dental and veterinary use; medical devices for the introduction of pharmaceutical preparations in the human body, in particular syringes and catheters; medical equipment, namely, centrifuges or other separation devices for the isolation of cell sub-populations from tissues and biopsies; surgical apparatus and instruments for medical and veterinary purpose; electrical medical instruments for use in electroporation of cells and tissues for gene transfer purposes, both in vivo and ex-vivo; electronic medical instruments for use in imaging for diagnostic purposes or for monitoring of vital signs of patients ] |
| Goods and Services | Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy |
| Goods and Services | Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; Providing medical and scientific research information and data on developments in the medical and veterinary fields; scientific and technological services, namely, scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; consultancy to ensure compliance with quality standards and the design and validation of manufacturing processes in the scientific field and medical technology fields |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 8, 2016 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 8, 2016 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 8, 2016 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | ANEMOCYTE S.R.L. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | GERENZANO (VA) I-21040 IT |
| Party Name | ARETA INTERNATIONAL S.R.L. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | IT |
| Party Name | ARETA INTERNATIONAL S.R.L. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | IT |
| Event Date | Event Description |
| Thursday, July 7, 2016 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, July 8, 2016 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, July 8, 2016 | ASSIGNED TO EXAMINER |
| Monday, July 11, 2016 | NON-FINAL ACTION WRITTEN |
| Tuesday, July 12, 2016 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, July 12, 2016 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, July 13, 2016 | REFUSAL PROCESSED BY MPU |
| Wednesday, July 13, 2016 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, July 29, 2016 | REFUSAL PROCESSED BY IB |
| Tuesday, October 11, 2016 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, October 11, 2016 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, November 16, 2016 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, December 7, 2016 | ASSIGNED TO LIE |
| Thursday, December 22, 2016 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, December 22, 2016 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sunday, January 8, 2017 | FINAL REFUSAL WRITTEN |
| Sunday, January 8, 2017 | FINAL REFUSAL E-MAILED |
| Sunday, January 8, 2017 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, February 1, 2017 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, February 1, 2017 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 1, 2017 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 1, 2017 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, February 1, 2017 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, February 1, 2017 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 1, 2017 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 1, 2017 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, February 1, 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, February 14, 2017 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Wednesday, March 1, 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, March 1, 2017 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, March 1, 2017 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Friday, March 17, 2017 | NOTIFICATION PROCESSED BY IB |
| Tuesday, March 21, 2017 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 21, 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 6, 2017 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, September 6, 2017 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Thursday, September 14, 2017 | FINAL DISPOSITION PROCESSED |
| Thursday, September 14, 2017 | FINAL DISPOSITION NOTICE SENT TO IB |
| Saturday, October 28, 2017 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Thursday, February 22, 2018 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Friday, April 9, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, June 6, 2022 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Monday, October 24, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Monday, October 24, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, October 24, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, October 24, 2022 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Monday, October 24, 2022 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Monday, October 24, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, October 24, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, June 5, 2023 | TEAS SECTION 71 RECEIVED |
| Monday, February 12, 2024 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Saturday, February 24, 2024 | POST REGISTRATION ACTION MAILED - SEC.71 |
| Wednesday, August 21, 2024 | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED |
| Friday, October 25, 2024 | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Friday, November 15, 2024 | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE |
| Friday, February 28, 2025 | REGISTERED-SEC.71 ACCEPTED |
| Friday, February 28, 2025 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED |
| Thursday, July 3, 2025 | INTERNATIONAL REGISTRATION RENEWED |
| Tuesday, September 30, 2025 | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Tuesday, October 28, 2025 | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED |